PepGen Inc. (NASDAQ:PEPG - Get Free Report) CEO James G. Mcarthur purchased 10,000 shares of the business's stock in a transaction on Thursday, April 17th. The shares were bought at an average cost of $1.35 per share, with a total value of $13,500.00. Following the acquisition, the chief executive officer now directly owns 113,913 shares of the company's stock, valued at $153,782.55. This trade represents a 9.62 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
PepGen Price Performance
Shares of NASDAQ PEPG traded down $0.15 during mid-day trading on Friday, reaching $1.53. The company's stock had a trading volume of 151,299 shares, compared to its average volume of 818,632. PepGen Inc. has a 52 week low of $0.88 and a 52 week high of $19.30. The stock has a fifty day moving average of $1.72 and a two-hundred day moving average of $3.50. The firm has a market capitalization of $50.02 million, a PE ratio of -0.51 and a beta of 1.42.
PepGen (NASDAQ:PEPG - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.13. Analysts anticipate that PepGen Inc. will post -2.73 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a "buy" rating and issued a $16.00 price target on shares of PepGen in a research report on Monday, February 24th.
Check Out Our Latest Stock Analysis on PEPG
Hedge Funds Weigh In On PepGen
Institutional investors have recently bought and sold shares of the stock. RTW Investments LP purchased a new stake in PepGen in the 4th quarter worth $12,102,000. Millennium Management LLC lifted its position in shares of PepGen by 1,033.2% in the fourth quarter. Millennium Management LLC now owns 156,636 shares of the company's stock worth $594,000 after buying an additional 142,814 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in PepGen during the fourth quarter valued at approximately $516,000. Bridgeway Capital Management LLC grew its holdings in PepGen by 103.1% during the 4th quarter. Bridgeway Capital Management LLC now owns 98,900 shares of the company's stock valued at $375,000 after buying an additional 50,200 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in PepGen by 442.5% in the 4th quarter. Deutsche Bank AG now owns 44,735 shares of the company's stock worth $170,000 after acquiring an additional 36,489 shares during the last quarter. 58.01% of the stock is owned by hedge funds and other institutional investors.
About PepGen
(
Get Free Report)
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
Recommended Stories
Before you consider PepGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PepGen wasn't on the list.
While PepGen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
